Specializes in developing and commercializing ready-to-use injectable and infusible drug formulations.
Xeris Biopharma Holdings, Inc. is a dynamic biopharmaceutical company dedicated to developing and commercializing innovative therapies across multiple therapeutic areas including endocrinology, neurology, and gastroenterology. At the forefront of its offerings is Gvoke, a ready-to-use liquid glucagon designed for the rapid treatment of severe hypoglycemia, addressing critical needs in diabetes management.
In addition to Gvoke, Xeris Biopharma markets Keveyis, a therapeutic option for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. The company also offers Recorlev, a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients suffering from Cushing's syndrome. These products exemplify Xeris' commitment to enhancing patient outcomes through advanced therapies.
Looking ahead, Xeris Biopharma maintains a robust pipeline of development programs aimed at expanding the applications of its existing products into new indications and uses. Leveraging its proprietary formulation technology platforms, XeriSol and XeriJect, the company continues to innovate and bring new therapeutic solutions to market.
Founded in 2005 .and headquartered in Chicago, Illinois, Xeris Biopharma Holdings operates with a mission to address unmet medical needs through scientific innovation and strategic partnerships. By focusing on advancing treatment options for complex medical conditions, Xeris Biopharma remains committed to making a meaningful impact on the lives of patients globally.